Zheng Quan Shi Bao Wang·2025-08-21 03:29Core Viewpoint - The company announced the completion of the first patient dosing in a registration clinical trial for its novel BCL2 inhibitor, mesutoclax (ICP-248), aimed at treating BTK inhibitor-treated mantle cell lymphoma (MCL) [1][2] Group 1: Product Development - Mesutoclax is a new oral, highly selective BCL2 inhibitor that targets the BCL2 protein, which is crucial in the apoptosis pathway and is linked to various malignant hematological tumors [1] - The unique mechanism of action of mesutoclax allows it to restore programmed cell death in tumor cells, demonstrating potential efficacy in treating MCL, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS) [1] - The registration clinical trial aims to evaluate the safety and efficacy of mesutoclax in patients with MCL who have previously been treated with BTK inhibitors, addressing a significant unmet need in this aggressive form of B-cell non-Hodgkin lymphoma [1] Group 2: Company Strategy - The co-founder, chairman, and CEO of the company expressed optimism that mesutoclax could provide new treatment hope for lymphoma patients and emphasized the commitment to accelerate its clinical development for both Chinese and global markets [2]